Search results
Results from the WOW.Com Content Network
The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. AstraZeneca bets on new cancer treatments with $2 billion Fusion ...
AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) (AZ) is a British-Swedish [2] [3] [4] multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. [5]
News. Science & Tech. Shopping. Sports. ... June 6, 2024 at 4:38 PM (Reuters) -Biomea Fusion said on Thursday the U.S. Food and Drug Administration had placed a clinical hold on ongoing studies of ...
Notable investments includes Fusion Pharmaceuticals, which was purchased by AstraZeneca for up to $2.4 billion in 2024, and Turnstone Biologics, which is listed on the Nasdaq stock exchange. [11] [12] It hosts an annual pitch competition called Falcons' Fortunes, in the style of the Dragons' Den television series.
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics ...
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL